Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Munmun Panda, Stuti Biswal, Bijesh K Biswal
BACKGROUND: In recent decades, phytotherapy has remained as a key therapeutic option for the treatment of various cancers. Evodiamine, an excellent phytocompound from Evodia fructus, exerts anticancer activity in several cancers by modulating drug resistance. However, the role of evodiamine in cisplatin-resistant NSCLC cells is not clear till now. Therefore, we have used evodiamine as a chemosensitizer to overcome cisplatin resistance in NSCLC. METHODS: Here, we looked into SOX9 expression and how it affects the cisplatin sensitivity of cisplatin-resistant NSCLC cells...
April 17, 2024: Molecular Biology Reports
#22
JOURNAL ARTICLE
Sidi Liu, Huichao Huang, Chunfang Zhang, Letao Chen, Xuelian Feng, Yaling Wu, Qing Xia, Xun Huang
The objective is to preliminary evaluated postoperative leukocyte counts as a surrogate for the surgical stress response in NSCLC patients who underwent RATS or VATS for further prospective analyses with proper assessment of surgical stress response and tissue trauma. We retrospectively analyzed patients with stageI-IIIA NSCLC who underwent RATS or VATS at a hospital between 8 May 2020 and 31 December 2021. Analysis of leukocytes (including neutrophils and lymphocytes) and albumin on postoperative days (PODs) 1 and 3 in patients with NSCLC treated with RATS or VATS after propensity score matching (PSM)...
April 17, 2024: Journal of Robotic Surgery
#23
JOURNAL ARTICLE
Xiaoshen Zhang, Xuanhe Wang, Yaokai Wen, Shen Chen, Caicun Zhou, Fengying Wu
BACKGROUND: Recurrent malignant pleural effusion (MPE) resulting from non-small-cell lung cancer (NSCLC) is easily refractory to conventional therapeutics and lacks predictive markers. The cellular or genetic signatures of recurrent MPE still remain largely uncertain. METHODS: 16 NSCLC patients with pleural effusions were recruited, followed by corresponding treatments based on primary tumours. Non-recurrent or recurrent MPE was determined after 3-6 weeks of treatments...
April 2024: Clinical and Translational Medicine
#24
JOURNAL ARTICLE
Muhammad Furqan, Siddharth Karanth, Ravi K Goyal, Beilei Cai, Julien Rombi, Keith L Davis, Nydia Caro, Teddy Saliba
Aim: To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14). Methods: In an oncologists-led retrospective review of medical records, data were abstracted and analyzed for patients initiating first-line (1L) systemic therapy after 1 January 2017. Results: In total 287 aNSCLC patients with METex14, the real-world best overall response rate was 73.4% for capmatinib (n = 146), 68.8% for immunotherapy (IO) monotherapy (n = 48), 52...
April 17, 2024: Future Oncology
#25
JOURNAL ARTICLE
Mathilde Marchand, Antonio Gonçalves, François Mercier, Pascal Chanu, Jin Y Jin, Jérémie Guedj, René Bruno
Model-based tumor growth inhibition (TGI) metrics are increasingly used to predict overall survival (OS) data in Phase III immunotherapy clinical trials. However, there is still a lack of understanding regarding the differences between two-stage or joint modeling methods to leverage Phase I/II trial data and help early decision-making. A recent study showed that TGI metrics such as the tumor growth rate constant KG may have good operating characteristics as early endpoints. This previous study used a two-stage approach that is easy to implement and intuitive but prone to bias as it does not account for the relationship between the longitudinal and time-to-event processes...
April 17, 2024: CPT: Pharmacometrics & Systems Pharmacology
#26
JOURNAL ARTICLE
Wei Wang, Kaicheng Shen, Ruyan Liu, Qi Zhou
BACKGROUND: Osteolytic bone metastasis is a common complication of Non-Small Cell Lung Cancer (NSCLC), resulting in bone pain, hypercalcemia, and fractures that severely reduce the quality of life and survival time of patients. Semaphorins 3A (Sema3A) is one of the isoforms of the Semaphorins family, which is important in a variety of physiological and pathological processes, such as angiogenesis, immune regulation, and tumorigenesis. However, the role of Sema3A in the development of osteolytic bone metastasis in NSCLC is unknown...
April 15, 2024: Recent Patents on Anti-cancer Drug Discovery
#27
JOURNAL ARTICLE
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Tetsu Kobayashi
BACKGROUND: Immune checkpoint inhibitors have recently become the standard of care in the first-line treatment of extensive-stage small cell lung cancer. Although immune-related adverse events have been reported to influence prognosis in non-small cell lung cancer patients, few studies have investigated the prognostic value of immune-related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune-related adverse events after first-line treatment with immune checkpoint inhibitor-based chemotherapy for extensive-stage small cell lung cancer...
April 2024: Cancer Medicine
#28
REVIEW
Shizhe Li, He Zhang, Ting Chen, Xiaowen Zhang, Guanning Shang
BACKGROUND: The proto-oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self-mutations or rearrangements. Studies on ROS1-directed tyrosine kinase inhibitors have been conducted, and some have been approved by the FDA for clinical use. However, the adverse effects and mechanisms of resistance associated with ROS1 inhibitors remain unknown. In addition, next-generation ROS1 inhibitors, which have the advantage of treating central nervous system metastases and alleviating endogenous drug resistance, are still in the clinical trial stage...
April 2024: Cancer Medicine
#29
JOURNAL ARTICLE
Tian-Xiang Zhang, Xin-Chun Duan, Yong Cui, Ye Zhang, Meng Gu, Zi-Yu Wang, Wei-Ying Li
PURPOSE: Dysregulated expression of microRNA (miRNAs) in lung cancer has been wildly reported. The clinicopathologic significance of miR-9-5p in non-small-cell lung cancer (NSCLC) patients and its effect on NSCLC progression were explored in this study. PATIENTS AND METHODS: A total of 76 NSCLC patients were included. miR-9-5p expression was evaluated by real-time quantitative polymerase chain reaction (RT-qPCR). Then, in vitro experiments including cell growth curve assays, colony formation assays, and transwell migration assays were performed...
2024: Frontiers in Oncology
#30
REVIEW
Peiyi Qin, Qingchen Li, Qi Zu, Ruxue Dong, Yuanfu Qi
Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) being the predominant type. The roles of autophagy and apoptosis in NSCLC present a dual and intricate nature. Additionally, autophagy and apoptosis interconnect through diverse crosstalk molecules. Owing to their multitargeting nature, safety, and efficacy, natural products have emerged as principal sources for NSCLC therapeutic candidates. This review begins with an exploration of the mechanisms of autophagy and apoptosis, proceeds to examine the crosstalk molecules between these processes, and outlines their implications and interactions in NSCLC...
2024: Frontiers in Oncology
#31
JOURNAL ARTICLE
Lan-Fang Li, Ran Qi, Tian-Tian Wei, Lei Feng, Xin Zhang, Qiao Liu
PURPOSE: The IPSOS study provided evidence supporting the efficacy and tolerability of first-line atezolizumab compared to single-agent chemotherapy for non-small-cell lung cancer (NSCLC) patients ineligible for treatment with a platinum-containing regimen. This study aimed to assess the cost-effectiveness of atezolizumab specifically in this population, considering the perspective of the Chinese healthcare system. PATIENTS AND METHODS: In this analysis, a three-state Markov model was utilized...
2024: Risk Management and Healthcare Policy
#32
JOURNAL ARTICLE
Jiongjie Wang, Jichao Guo, Haizhan Shi, Xiangru Chen, Wenxin He, Zhixin Li
OBJECTIVES: The right lower sleeve lobectomy is a rarely performed major lung resection.This study aims to evaluate the safety and effectiveness of this procedure by comparing to right lower bilobectomy in non-small cell lung cancer patients. METHODS: We retrospectively reviewed a prospective database of non-small cell lung cancer patients who underwent right lower sleeve lobectomy (group S) or right lower bilobectomy (group B) from January 2014 to January 2020 in Shanghai Pulmonary Hospital...
April 16, 2024: Journal of Cardiothoracic Surgery
#33
JOURNAL ARTICLE
Yanmin Zhang, Gaoming Wang, Qian Zhang, Qian Wang, Jing Luo, Chunhua Ling
OBJECTIVE: The aim of this study is to investigate the clinical value and potential prognostic significance of lung function assessment and Testin expression in non-small cell lung cancer (NSCLC) patients. METHODS: The NSCLC patients were classified into three groups according to lung function: group of normal lung function, group of PRISm (preserved ratio impaired spirometry) (FEV1, forced expiratory volume during the first second < 80% predicted and FEV1/FVC (forced vital capacity) ≥ 70%) and group of COPD (chronic obstructive pulmonary disease) (FEV1/FVC < 70%)...
April 16, 2024: Journal of Cardiothoracic Surgery
#34
REVIEW
David Planchard, Rachel E Sanborn, Marcelo V Negrao, Aria Vaishnavi, Egbert F Smit
In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAFV600E mutation confers constitutive activity of the MAPK pathway, leading to enhanced growth, proliferation, and survival of tumor cells. Testing for BRAF mutations enables patients to be treated with therapies that directly target BRAFV600E and the MAPK pathway, but BRAF testing lags behind other oncogene testing in metastatic NSCLC...
April 16, 2024: NPJ Precision Oncology
#35
JOURNAL ARTICLE
Yanhua Wang, Jingwen Wei, Manyi Xu, Jing Xiang, Keda Shao, Yue Hao, Zhengbo Song
BACKGROUND: Mesenchymal epithelial transition factor (MET) is a rare oncologic driver gene, and information on immunotherapy for non-small cell lung cancer (NSCLC) patients with this driver gene is limited. Here we evaluate the efficacy and safety of immune checkpoint inhibitors (ICI) under different therapeutic regimen for NSCLC patients with MET alterations. METHODS: From June 2019 to December 2023, we assessed the efficacy and toxicity of ICIs in 42 NSCLC patients with MET alterations...
April 16, 2024: Clinical & Translational Oncology
#36
Filippo Tommaso Gallina, Marco Chiappetta, Riccardo Tajè, Daniele Forcella, Carolina Sassorossi, Maria Teresa Congedo, Jessica Evangelista, Isabella Sperduti, Filippo Lococo, Federico Cappuzzo, Enrico Melis, Stefano Margaritora, Francesco Facciolo
No abstract text is available yet for this article.
March 15, 2024: Clinical Lung Cancer
#37
JOURNAL ARTICLE
Jessica Donington, Xiaohan Hu, Su Zhang, Yan Song, Ashwini Arunachalam, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch, Ayman Samkari
BACKGROUND: Novel neoadjuvant chemoimmunotherapy treatments are being investigated for locally advanced non-small-cell lung cancer (NSCLC), but real-world outcomes for neoadjuvant treatments are poorly understood. This study examined neoadjuvant treatment patterns, real-world event-free survival (rwEFS) and overall survival (OS) in patients with resected, stage II-III NSCLC in the United States (US). METHODS: This retrospective study identified patients in the SEER-Medicare database (2007-2019) with newly diagnosed stage II, IIIA, and IIIB (N2) NSCLC (AJCC 8th edition) treated with neoadjuvant chemo/chemoradiotherapy and resection (index date: neoadjuvant therapy initiation)...
March 22, 2024: Clinical Lung Cancer
#38
JOURNAL ARTICLE
Natalie K Horvat, Sara Chocarro, Oriana Marques, Tobias A Bauer, Ruiyue Qiu, Alberto Diaz-Jimenez, Barbara Helm, Yuanyuan Chen, Stefan Sawall, Richard Sparla, Lu Su, Ursula Klingmüller, Matthias Barz, Matthias W Hentze, Rocío Sotillo, Martina U Muckenthaler
ALK-positive NSCLC patients demonstrate initial responses to ALK tyrosine kinase inhibitor (TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor survival rates. Growing evidence suggests that the combination of drug and immune therapies greatly improves patient survival; however, due to the low immunogenicity of the tumors, ALK-positive patients do not respond to currently available immunotherapies. Tumor-associated macrophages (TAMs) play a crucial role in facilitating lung cancer growth by suppressing tumoricidal immune activation and absorbing chemotherapeutics...
April 16, 2024: ACS Nano
#39
JOURNAL ARTICLE
Zihan Sun, Xiaoyue Xiao, Shuo Liang, Haiyue Ma, Yue Sun, Linlin Zhao, Cong Wang, Xinxiang Chang, Huan Zhao, Huiqin Guo, Zhihui Zhang
In clinical practice, PD-L1 detection is prone to nonspecific staining due to the complex cellular composition of pleural effusion smears. In this study, DAB and AEC immunohistochemistry (IHC) double staining was performed to investigate PD-L1 expression in tumor cells from malignant pleural effusion (MPE). MPE was considered as a metastasis in non-small cell lung cancer (NSCLC) patients, thus, the heterogeneity between metastatic and primary lung cancer was revealed as well. Ninety paired specimens of MPE cell blocks (CBs) and matched primary lung cancer tissues from NSCLC patients were subjected to PD-L1 and TTF-1/p63 IHC double staining...
April 14, 2024: Laboratory Investigation; a Journal of Technical Methods and Pathology
#40
JOURNAL ARTICLE
Joline Ingels, Laurenz De Cock, Dieter Stevens, Rupert L Mayer, Fabien Théry, Guillem Sanchez Sanchez, David Vermijlen, Karin Weening, Saskia De Smet, Nele Lootens, Marieke Brusseel, Tasja Verstraete, Jolien Buyle, Eva Van Houtte, Pam Devreker, Kelly Heyns, Stijn De Munter, Sandra Van Lint, Glenn Goetgeluk, Sarah Bonte, Lore Billiet, Melissa Pille, Hanne Jansen, Eva Pascal, Lucas Deseins, Lies Vantomme, Maarten Verdonckt, Ria Roelandt, Thomas Eekhout, Niels Vandamme, Georges Leclercq, Tom Taghon, Tessa Kerre, Floris Vanommeslaeghe, Annemieke Dhondt, Liesbeth Ferdinande, Jo Van Dorpe, Liesbeth Desender, Frederic De Ryck, Frank Vermassen, Veerle Surmont, Francis Impens, Björn Menten, Karim Vermaelen, Bart Vandekerckhove
Non-small cell lung cancer (NSCLC) is known for high relapse rates despite resection in early stages. Here, we present the results of a phase I clinical trial in which a dendritic cell (DC) vaccine targeting patient-individual neoantigens is evaluated in patients with resected NSCLC. Vaccine manufacturing is feasible in six of 10 enrolled patients. Toxicity is limited to grade 1-2 adverse events. Systemic T cell responses are observed in five out of six vaccinated patients, with T cell responses remaining detectable up to 19 months post vaccination...
April 9, 2024: Cell reports medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
